Table 3.

ORs for associations between serum lipid levels and the presence and extent of baseline chronic prostate inflammation in REDUCE

Presence of chronic inflammationExtent of chronic inflammation
NoneAnyNoneModerate; <20% of coresSevere; ≥20% of cores
nnOR (95% CI)nnOR (95% CI)nOR (95% CI)
Total cholesterol
 <200 mg/dL264998126437916051
 200–239 mg/dL9083,0550.94 (0.80–1.09)9081,1530.92 (0.77–1.10)1,8660.95 (0.80–1.12)
 ≥240 mg/dL3321,0980.92 (0.76–1.11)3324060.89 (0.71–1.10)6810.95 (0.77–1.16)
Ptrend0.6570.5010.854
LDL
 <130 mg/dL7332,591173396911,5831
 130–159 mg/dL4241,4961.03 (0.90–1.19)4245681.04 (0.88–1.23)9171.05 (0.90–1.22)
 ≥160 mg/dL3471,0640.94 (0.80–1.10)3474010.93 (0.78–1.12)6520.95 (0.80–1.12)
Ptrend0.2850.3130.374
HDL
 <40 mg/dL2711,053127140416361
 40–59 mg/dL9433,1390.89 (0.77–1.04)9431,1790.87 (0.73–1.04)1,9210.90 (0.77–1.07)
 ≥60 mg/dL2909590.91 (0.75–1.11)2903550.88 (0.70–1.11)5950.94 (0.76–1.15)
Ptrend0.9930.8570.848
Triglycerides
 <150 mg/dL9533,32619531,25312,0381
 150–199 mg/dL2799561.00 (0.86–1.17)2793631.00 (0.84–1.20)5750.99 (0.84–1.17)
 ≥200 mg/dL2728690.93 (0.79–1.09)2723220.90 (0.75–1.09)5390.94 (0.80–1.12)
Ptrend0.3290.2760.508
  • NOTE: ORs were adjusted for age at baseline (continuous), race (white, non-white), geographic region (North America, Europe, other), BMI (continuous, log-transformed), smoking status (never, former, current), statin use (no, yes), and NSAID use (no, yes).